NCLAT Sets Aside CIRP Order Against Shilpa Medicare Subsidiary FTF Pharma
Shilpa Medicare Ltd 路 Others (Uncategorized) 路 05 Nov 2026, 10:14 pm
NCLAT Sets Aside CIRP Order Against Shilpa Medicare Subsidiary FTF Pharma NCLAT, vide its order dated 4th Nov'26, set aside the NCLT Ahmedabad Bench order dated 9th Sep'26 that had initiated Corporate Insolvency Resolution Process (CIRP) against FTF Pharma Private Limited, a wholly owned subsidiary of Shilpa Medicare Limited. The Section 9 application filed by operational creditor Immacule Lifesciences for Rs 2.18 cr was rejected due to pre-existing disputes and mutual resolution. Consequently, the CIRP and Section 14 moratorium stand annulled, the Interim Resolution Professional is discharged, and management control is restored with zero financial impact on Shilpa Medicare.
Original exchange filing (PDF)
More announcements from Shilpa Medicare Ltd
- Q2FY27 Earnings Conference Call 05 November 2026 路 11 Nov 2026
- Audio link of the Investor Conference call for the quarter ended 30 September 2026. 路 06 Nov 2026
- Investor Presentation for the Quarter and Half year ended 30 September 2026 路 05 Nov 2026
- Outcome of the Board Meeting 路 05 Nov 2026
- Shilpa Medicare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Financial Results for the Quarter and Half year ended 30 September 2026 路 05 Nov 2026
- SHILPA MEDICARE LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 05 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 路 05 Nov 2026
